Denali partner Sanofi reports Phase 2 ALS trial miss for RIPK1 inhibitor DNL788

Denali Therapeutics Inc.

Phase 2 HIMALAYA study of SAR443820/DNL788 in ALS did not meet primary endpoint (ALSFRS-R).
Sanofi will present detailed efficacy and safety results at a future scientific forum.
DNL788 is an oral brain-penetrant RIPK1 inhibitor co-developed by Sanofi and Denali.
Sanofi will continue the K2 Phase 2 study of DNL788 in multiple sclerosis.
No financial terms disclosed; pipeline setback for Denali's key partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.